Abstract
Drug delivery through mouth is still the most acceptable route to administer bioactives for the patient. The colon targeted drug delivery has gained increasing attention towards the treatment of colorectal cancer and other colon related disorders i.e., Crohn's disease, ulcerative colitis, irritable bowel syndrome, and spastic colon. The drugs such as cardiovascular and antiasthmatic agents have also been delivered via colon to avoid first pass metabolism or acidic environment of stomach. Colon targeting has also been demonstrated as a potential tool for systemic delivery of protein/peptide drugs due to relatively low proteolytic activities in the colonic environment. The GIT is dwelt by over 500 bacterial species, each having a specific place in the tract and developing variety of enzymes which are being utilized for development of colon-targeted drug delivery systems. There are various strategies presently followed for colontargeted delivery i.e., prodrugs that become active at the colonic site, drug-eluting system reacting to the pH, microfloraactivated drug delivery systems, hydrogels and matrices, and multicoating time-dependent drug delivery systems. The future steering towards colon targeted bioactives delivery would involve the application of specific binding with colonic mucosa.
Keywords: CDDS, colon specific drug delivery, nanoparticle, prodrug.
Current Drug Therapy
Title:Colon as Target for Drug Delivery
Volume: 9 Issue: 1
Author(s): Anamika Sahu, Aviral Jain and Arvind Gulbake
Affiliation:
Keywords: CDDS, colon specific drug delivery, nanoparticle, prodrug.
Abstract: Drug delivery through mouth is still the most acceptable route to administer bioactives for the patient. The colon targeted drug delivery has gained increasing attention towards the treatment of colorectal cancer and other colon related disorders i.e., Crohn's disease, ulcerative colitis, irritable bowel syndrome, and spastic colon. The drugs such as cardiovascular and antiasthmatic agents have also been delivered via colon to avoid first pass metabolism or acidic environment of stomach. Colon targeting has also been demonstrated as a potential tool for systemic delivery of protein/peptide drugs due to relatively low proteolytic activities in the colonic environment. The GIT is dwelt by over 500 bacterial species, each having a specific place in the tract and developing variety of enzymes which are being utilized for development of colon-targeted drug delivery systems. There are various strategies presently followed for colontargeted delivery i.e., prodrugs that become active at the colonic site, drug-eluting system reacting to the pH, microfloraactivated drug delivery systems, hydrogels and matrices, and multicoating time-dependent drug delivery systems. The future steering towards colon targeted bioactives delivery would involve the application of specific binding with colonic mucosa.
Export Options
About this article
Cite this article as:
Sahu Anamika, Jain Aviral and Gulbake Arvind, Colon as Target for Drug Delivery, Current Drug Therapy 2014; 9 (1) . https://dx.doi.org/10.2174/1574885509666140805003632
DOI https://dx.doi.org/10.2174/1574885509666140805003632 |
Print ISSN 1574-8855 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3903 |
Call for Papers in Thematic Issues
Novel Therapeutic Approaches and Biomarkers for Chronic Kidney Disease (CKD)
The thematic issue on "Novel Therapeutic Approaches and Biomarkers for CKD" aims to provide a comprehensive exploration of cutting-edge strategies for the management of chronic kidney disease (CKD). This issue will delve into emerging therapeutic targets, focusing on critical aspects such as podocyte injury, endothelial dysfunction, and tubulointerstitial fibrosis, which ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Tanshinone IIA Alleviates the Biological Characteristics of Colorectal Cancer via
Activating the ROS/JNK Signaling Pathway
Anti-Cancer Agents in Medicinal Chemistry Inhibitors of the HSP90 Molecular Chaperone: Attacking the Master Regulator in Cancer
Current Topics in Medicinal Chemistry The Role of LncRNA TUG1 in Obesity-related Diseases
Mini-Reviews in Medicinal Chemistry Survey on the Techniques for Classification and Identification of Brain Tumour Types from MRI Images Using Deep Learning Algorithms
Recent Advances in Computer Science and Communications Antigenic Peptide Vaccination: Provoking Immune Response and Clinical Benefit for Cancer
Current Immunology Reviews (Discontinued) Design and Synthesis of 4(1H)-quinolone Derivatives as Autophagy Inducing Agents by Targeting ATG5 Protein
Letters in Drug Design & Discovery Development of New Potential Anticancer Metal Complexes Derived from 2-Hydrazinobenzothiazole
Mini-Reviews in Medicinal Chemistry Chronic Inflammation and Colorectal Cancer: The Role of Vascular Endothelial Growth Factor
Current Pharmaceutical Design Anti-Cancer Activity of Synthesized 5-Benzyl juglone on Selected Human Cancer Cell Lines
Anti-Cancer Agents in Medicinal Chemistry An Overview of Recent Findings that Shed Light on the Connection between Fat and Cancer
Endocrine, Metabolic & Immune Disorders - Drug Targets In Silico Identification of Human miR 3654 and its Targets Revealed its Involvement in Prostate Cancer Progression
MicroRNA Pharmacokinetics and In Vivo Fate of Drug Loaded Chitosan Nanoparticles<sup>++</sup>
Current Drug Metabolism Vitamin D: Evolutionary, Physiological and Health Perspectives
Current Drug Targets Targeting JAK3 Tyrosine Kinase-Linked Signal Transduction Pathways with Rationally-Designed Inhibitors
Anti-Cancer Agents in Medicinal Chemistry KIR Molecules: Recent Patents of Interest for the Diagnosis and Treatment of Several Autoimmune Diseases, Chronic Inflammation, and B-cell Malignancies
Recent Patents on DNA & Gene Sequences Thalidomide Derived Immunomodulatory Drugs (IMiDs) as Potential Therapeutic Agents
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Impact of p53 arg72pro SNP on Breast Cancer Risk in North Indian Population
Current Genomics Medicinal Attributes of Imidazo[1,2-a]pyridine Derivatives: An Update
Current Topics in Medicinal Chemistry Clinical Trials Targeting Advanced Cancers by Active Immunization of T-cell Defined Tumor Antigens
Current Pharmaceutical Design <i>Carica papaya</i> in Cancer Prevention: An Overview
Mini-Reviews in Medicinal Chemistry